Final Program in it's entirety - MyGirlsBlood

Recommendations

Info

Posters, Sunday and Monday Index of Poster Presenters cont’d 08P09 Same Prevalence but Low Response of Inhibitors in African Hemophiliacs Receiving Low Quantity of Factor Concentrates Saliou D, Aïssatou S, Moussa S, Bamar Guèye Y, Dièye T, Oumar AT, Sall A, Thiam D, Diakhaté L Service d’Hématologie, Université Cheikh Anta Diop, Dakar, Sénégal 08P10 Functional Characterization of Recombinant GlycoPEGylated FIX (40K PEG-rFIX) after Intravenous Administration to Hemophilia B dogs (HB) Ezban M1 , Hansen L1 , Hermit M1 , Tranholm M1 , Østergård H1 , Nichols T2 1 2 Novo Nordisk A/S, Maaloev, Denmark University of North Carolina, Chapel Hill, North Carolina, U.S.A. 08P11 Levels of Transforming Growth Factor- (Tgf- ) in Concentrates of Factor VIII Manufactured in Unc-Hemoderivados Farias F, Guglielmone H, Navarro D, Moya C and Vitali MS Area de Desarrollo de Productos y Procesos, UNC- Hemoderivados, Córdoba, Argentina 08P12 Restoration of Thrombin Generation in Factor XI-Deficient Plasma Using a Factor XI Concentrate Feldman P, Hardway C Bio Products Laboratory, Elstree, U.K. 08P13 BERIATE®P in the Treatment of Patients with Hemophilia A: Update of a Long-Term Pharmacovigilance Klamroth R1 , Zimmermann R2 , Kurnik K3 , Holzhauer S4 , Geist M5 1 2 Vivantes Klinikum Berlin, Germany, Kurpfalzkrankenhaus Heidelberg, Germany, 3Dr. v. Haunersches Childrens Hospital Munich, Germany, 4University Hospital Charité Berlin, Germany, 5CSL Behring, Germany 08P14 Update of a Long-Term Pharmacovigilance Project: Helixate® NexGen for the Treatment of Hemophilia A Oldenburg J1 , Petrini P2 , Santagostino E3 , Pabinger I4 , Geist M5 , Lenk H6 1 2 University Hospital Bonn, Germany, Karolinska Sjukhuset Stockholm, Sweden, 3A. Bianchi Bonomi Haemophilia Center Milan, Italy, 4University Hospital Vienna, Germany, 5CSL Behring GmbH, Germany, 6University Hospital Leipzig, Germany 52 08P15 An Accurate and Routinely Adapted Enzyme-Linked Immunosorbent Assay for Type 2N von Willebrand Disease Diagnosis Caron C 1 , Ternisien C 2 , Wolf M 3 , Fressinaud E 3 , Veyradier A 3 , Goudemand J 1 for the National Reference Centre on von Willebrand disease (CRMW) Hematology Department of 1 Lille, 2 Nantes, 3 Clamart, France 08P16 Prolonged Circulatory Half Life for rFVIIa After Conjugation to Hydroxyethy1 Starch Hey T and Hackett F Fresenius Kabi Deutschland GmbH, HESylation® Technology, Friedberg, Germany 08P17 Generation of Recombinant FVIII Purification Antibody of N8 Hansen J, Bolt G, Kjærgaard K, Kristensen C, Steenstrup T Novo Nordisk A/S 08P18 Concept and Structure Model of Factor IX Albumin Fusion Proteins Horn C1 , Steuber H2 , Metzner H1 , Kuo W1 , Weimer T1 , Schulte S1 1 2 CSL Behring GmbH, Marburg, Germany, Institute of Biochemistry, University of Lübeck, Germany 08P19 Concept and Structure Model of Factor VIIa Albumin Fusion Proteins Horn C1 , Steuber H2 , Weimer T1 , Wormsbächer W1 , Liebing U1 , Kuo W1 1 2 CSL Behring GmbH, Marburg, Germany, Institute of Biochemistry, University of Lübeck, Germany 08P20 Therapy by rFVIIa (Novoseven) in Patients with Hemophilia A and Inhibitor: Factors Influencing Total Therapy Effectiveness Hulíková M 1 , Hulíková J1 , Brabec P2 1Center of Haemostasis and Thrombosis, Hemo Medika, Košice, Slovakia, 2Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic 08P21 Transforming Growth Factor Beta (TGF- 1) Content in Octanate ® – Assessment and Methodological Issues Kannicht C, Fisseau C, Fuchs B Octapharma R&D, Molecular Biochemistry, Berlin, Germany
Index of Poster Presenters cont’d 08P22 An Ultrapure Plasma-Derived Monoclonal Antibody Purified Factor IX Concentrate, Results of the Phase III and IV Clinical Study Mauser-Bunschoten E1 , Kleine Budde I2 , Lopaciuk S3 , Koopman MMW4 , van der Meer FJM5 , Novàkovà IRO6 , Ypma P 7 , van der Linden PWG 8 , Strengers PFW2 1Van Creveldkliniek and Hematology, University Medical Centre Utrecht, Utrecht, the Netherlands, 2Sanquin Blood Supply Foundation, Amsterdam, the Netherlands, 3Institute of Hematology and Blood Transfusion, Warsaw, Poland, 4 5 Academisch Medisch Centrum, Amsterdam, Leiden University Medical Centre, Leiden, 6University Medical Centre St. Radboud, Nijmegen, 7HAGA Hospital, location Leyenburg, Den Haag, 8Kennemer Hospital, location EG, Haarlem, the Netherlands 08P23 Low Inhibitor Incidence in Previously Untreated Hemophilia A Patients (PUPs) Treated with Octanate ® Klukowska A1 , Laguna P1 , Komrska V2 , Jansen M3 1 2 Warsaw Medical University, Russia, FN Motol, Czech Republic, 3Octapharma, Austria 08P24 In-Vitro Immunogenicity Studies of a New High Purity Factor X Concentrate Lloyd J, John E, Feldman P Bio Products Laboratory, Elstree, U.K. 08P25 Purification of Blood Clotting Factor VII: Suitable for Therapeutic Application Madych S, Danysh T Institute of Blood Pathology and Transfusion Medicine, UAMS, Lviv, Ukraine 08P26 NovoSeven® for Surgery in Inherited FVII Deficiency: Data from STER (Seven Treatment Evaluation Registry) Mariani G1 , Batorova A2 , Ingerslev J3 , Auerswald G4 , Schved J5 , Siragusa S6 1Internal Medicine & Hematology Unit, University of L’Aquila, Italy, 2The National Haemophilia Centre, Institute of Haematology and Blood Transfusion, University Hospital, Bratislava, Slovakia, 3Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Skejby, Aarhus N Denmark, 4Department of Pediatrics, Central Hospital, Bremen, 5 Germany, Hemophilia & Thrombosis Centre CHU Montpellier, France, 6Hematology, University of Palermo, Italy 08P27 Efficacy and Safety of KOGENATE ® Bayer in Patients with Hemophilia A During Surgical Procedures Miesbach W, Krekeler S, Alesci S University Hospital Frankfurt, Germany 08P28 Bioequivalence of B-Domain Deleted and Plasma Derived FVIII Concentrates Morfini M1 , Iorio A2 , Mazzucconi M3 , Cinotti S1 , Zanon E4 , Paladino E1 1 2 Hemophilia Centre of Florence, University of Perugia, 3Hemophilia Centre of Rome- La Sapienza University, 4Hemophilia Centre of Padova, Italy 08P29 A Survey of FVIII Use in 19 European Countries O’Mahony B Irish Haemophilia Society, Dublin, Ireland 08P30 The Effect of Reduced Sampling Time Points in a Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A Oh M1 , Björkman S2 , Schroth P1 , Fritsch S1 , Collins PW3 , Fischer K4 , Blanchette VS5 , Casey K1 , Spotts GD1 , and Ewenstein BM1 , for the rAHF-PFM Clinical Study Group 1 2 Baxter BioScience, Austria and US, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden, 3University Hospital of Wales, Cardiff, U.K., 4Van Creveldkliniek, University Medical Center, Utrecht, NL, 5Hospital for Sick Children, Toronto, ON, Canada 08P31 Effect of Different Monoclonal Anti-FVIII-Antibodies on the Hemostatic Activity of Plasma-Derived and Recombinant FVIII-Concentrates in Absence and Presence of VWF Pillitteri D, Scholz T, Krause M, Kirchmaier C German Diagnostic Clinic, Wiesbaden, Germany 08P32 Hemophilia Treatment in Serbia in 2009 – Quantity of Products and Frequency of Therapy Complications Rakic L, Mikovic D, Jankovic G, Kovac M, Maslac A Blood Transfusion Institute of Serbia, Belgrade, Serbia 08P33 Product Characteristics of Human Cell Line Recombinant Factor VIII, (Human-cl rhFVIII) Sandberg H1 , Ramström M1 , Stenlund P1 , Kannicht C2 , Agerkvist I1 1 2 Octapharma AB, Stockholm, Sweden, Octapharma, Molecular Biochemistry, Berlin, Germany 53 Posters, Sunday and Monday
Page 1 and 2: Hemophilia Saturday, July 10 - Wedn
Page 3 and 4: Pre-Congress Sessions cont’d 10:3
Page 5 and 6: Pre-Congress Sessions cont’d 15:0
Page 7 and 8: Congress Sessions cont’d S1.6 - M
Page 9 and 10: Congress Sessions cont’d S2.5 - M
Page 11 and 12: Congress Sessions cont’d n Long T
Page 13 and 14: Congress Sessions cont’d M2.4 - M
Page 15 and 16: Congress Sessions cont’d Tuesday,
Page 17 and 18: Congress Sessions cont’d 14:15 -
Page 19 and 20: Congress Sessions cont’d T3.4 - M
Page 21 and 22: Congress Sessions cont’d n Inhibi
Page 23 and 24: Congress Sessions cont’d W2.4 - L
Page 25 and 26: Index of Speakers cont’d Halimeh,
Page 27 and 28: Index of Poster Presenters Sunday a
Page 29 and 30: Index of Poster Presenters cont’d
Page 37: Index of Poster Presenters cont’d

Final Program in it's entirety - MyGirlsBlood

Create successful ePaper yourself

Delete template?

Save as template?